| Texto completo | |
| Autor(es): Mostrar menos - |
Silveira, Douglas R. A.
[1, 2, 3]
;
Coelho-Silva, Juan L.
[4]
;
Silva, Wellington F.
[5]
;
Vallance, Grant
[6]
;
Pereira-Martins, Diego A.
[4]
;
Madeira, Maria I. A.
[4]
;
Figueredo-Pontes, Lorena L.
[4]
;
Velloso, Elvira D. R. P.
[2, 3, 5]
;
Simoes, Belinda P.
[4]
;
Peniket, Andy
[6]
;
Danby, Robert
[6]
;
Rego, Eduardo M.
[2, 3, 5]
;
Vyas, Paresh
[6, 7]
;
Traina, Fabiola
[4]
;
Bendit, Israel
[2, 3]
;
Quek, Lynn
[8]
;
Rocha, Vanderson
[2, 3, 5, 6]
Número total de Autores: 17
|
| Afiliação do(s) autor(es): | [1] AC Camargo Canc Ctr, Dept Hematol, Sao Paulo - Brazil
[2] Univ Sao Paulo, Med Sch, Serv Hematol Transfus & Cell Therapy, Sao Paulo - Brazil
[3] Univ Sao Paulo, Med Sch, Lab Med Invest Pathogenesis & Directed Therapy On, Sao Paulo - Brazil
[4] Univ Sao Paulo, Ribeirao Preto Med Sch FMRP, Dept Med Images Hematol & Clin Oncol, Ribeirao Preto - Brazil
[5] Univ Sao Paulo, Canc Inst Sao Paulo ICESP, Leukemia Unit, Med Sch, Sao Paulo, SP - Brazil
[6] Oxford Univ Hosp NHS Fdn Trust, Dept Haematol, Oxford - England
[7] Univ Oxford, Radcliffe Dept Med, Oxford Ctr Hematol, WIMM, MRC MHU, BRC Haematol Theme, Oxford Biomed Res Ctr, Oxford - England
[8] Kings Coll Hosp NHS Fdn Trust, Dept Haematol Med, London - England
Número total de Afiliações: 8
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Leukemia & Lymphoma; v. 62, n. 1, p. 147-157, JAN 2 2021. |
| Citações Web of Science: | 0 |
| Resumo | |
Outcomes in acute myeloid leukemia (AML) are dependent on patient- and disease-characteristics, treatment, and socioeconomic factors. AML outcomes between resource-constrained and developed countries have not been compared directly. We analyzed two cohorts: from Sao Paulo state, Brazil (USP,n = 312) and Oxford, United Kingdom (OUH,n = 158). USP cohort had inferior 5-year overall survival compared with OUH (29% vs. 49%, adjusted-p=.027). USP patients have higher early-mortality (23% vs. 6%p<.001) primarily due to multi-resistant Gram-negative bacterial and fungal infections. USP had higher 5-year cumulative incidence of relapse (60% vs. 50%,p=.0022), were less likely to undergo hematopoietic stem cell transplant (HSCT) (28% vs. 75%,p<.001) and waited longer for HSCT (median, 23.8 vs. 7.2 months,p<.001). Three-year survival in relapsed patients was worse in USP than OUH (10% vs. 39%,p<.001). Our study indicates that efforts to improve AML outcomes in Brazil should focus on infection prevention and control, and access to HSCT. (AU) | |
| Processo FAPESP: | 16/23191-4 - Investigação da Participação de IRS2 na patogênese de neoplasias mieloproliferativas JAK2V617F utilizando modelos murinos |
| Beneficiário: | Juan Luiz Coelho da Silva |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |
| Processo FAPESP: | 17/23117-1 - Avaliação da via TP53/TP73 na enxertia de células de leucemia promielocítica aguda em modelo de xenotransplante |
| Beneficiário: | Diego Antonio Pereira Martins |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |